YUTIQ Drug Patent Profile

When do Yutiq patents expire, and what generic alternatives are available?

Yutiq is a drug marketed by Alimera Sciences Inc and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and seventy-seven patent family members in twenty-seven countries.

The generic ingredient in YUTIQ is fluocinolone acetonide. There are twelve drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Yutiq

A generic version of YUTIQ was approved as fluocinolone acetonide by FOUGERA PHARMS INC on December 16^th, 1982.

Summary for YUTIQ

International Patents:	177
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for YUTIQ

US Patents and Regulatory Information for YUTIQ

YUTIQ is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alimera Sciences Inc	YUTIQ	fluocinolone acetonide	IMPLANT;INTRAVITREAL	210331-001	Oct 12, 2018		RX	Yes	Yes	7,998,108		Y
Alimera Sciences Inc	YUTIQ	fluocinolone acetonide	IMPLANT;INTRAVITREAL	210331-001	Oct 12, 2018		RX	Yes	Yes	8,871,241		Y

International Patents for YUTIQ

See the table below for patents covering YUTIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4619795
Taiwan	I345987
South Korea	20100120243	PROCESSES FOR FORMING A DRUG DELIVERY DEVICE

Supplementary Protection Certificates for YUTIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2233112	122014000063	Germany		PRODUCT NAME: FLUOCINOLONACETONID; NAT. REGISTRATION NO/DATE: 82809.00.00 20120720; FIRST REGISTRATION: GB PL 27813/0001 20120504
2233112	132014902285293	Italy		PRODUCT NAME: FLUOCINOLONE ACETONIDE(ILUVIEN); AUTHORISATION NUMBER(S) AND DATE(S): 042616019, 20140530;PL27813/0001, 20120504

Analysis of YUTIQ: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

YUTIQ (fluocinolone acetonide intravitreal implant) is an ophthalmic pharmaceutical product developed by Alimera Sciences, approved in multiple markets for the treatment of posterior segment uveitis. This report analyzes the current investment landscape, market dynamics, and projected financial trajectory of YUTIQ, emphasizing its commercial potential, competitive positioning, regulatory environment, and growth prospects.

---

Overview of YUTIQ and Its Approved Indications

Attribute	Details
Generic Name	Fluocinolone acetonide implant
Brand Name	YUTIQ
Developer	Alimera Sciences
Approval Date(s)	FDA (2018), EMA (2019), other jurisdictions vary
Primary Indication	Non-infectious posterior segment uveitis in adults
Administration	Intravitreal injection during ophthalmic procedures
Duration of Effect	Up to 36 months (per clinical data)

YUTIQ’s sustained-release formulation targets chronic ocular inflammation, offering a treatment alternative to corticosteroid eye drops or repeat injections.

---

Investment Landscape of YUTIQ

Market Potential and Revenue Generation

Metric	Scope	Data Points	Source / Notes
Market Size (Global)	Uveitis treatment	$0.8 billion (2022)	[1]
Addressable Patients (US)	Uveitis prevalence	~107,000 (adults)	[2]
Market Penetration Goals	10-20% in initial years	Conservative estimates	Industry reports
Average Selling Price (ASP)	Per implant	$4,000-$5,000	Commercial data
Potential Year 1 Revenue (US)	Assuming 10% penetration	~$40-50 million	Internal estimates

Note: YUTIQ’s revenue is bitesize, contingent upon market acceptance, competitive dynamics, and insurance reimbursement.

Growth Drivers and Barriers

Drivers	Barriers	Remarks
Increasing uveitis prevalence	Limited awareness	Education campaigns needed
Long-term efficacy of YUTIQ	Competitive therapies	Includes Ozurdex (Dexamethasone implant)
Favorable reimbursement policies	Manufacturing capacity	Ensuring supply chain scalability
Physician acceptance of sustained-release	Off-label use limitations	Regulatory clarity essential

Competition Landscape

Competitor	Key Features	Clinical Status	Market Share	Notes
Ozurdex (Dexamethasone)	Biodegradable implant, 3-6 months duration	Approved, broader indications	~40%	Established product, widespread use
Retisert (Fluocinolone)	Non-biodegradable, 30-month release	Approved, limited use	Small	High complication profile
Iluvien (Fluocinolone)	36-month implant, approved in Europe & US	Competitive	Growing	Key competitor for YUTIQ

YUTIQ’s competitive edge lies in its consistent release profile and fewer procedural complications.

---

Market Dynamics Impacting Financial Trajectory

Regulatory and Reimbursement Factors

• FDA Approvals: Market entry since 2018; aligned with post-approval studies supporting efficacy.
• Insurance Reimbursements: Critical for revenue realization; positive policy shifts observed in US and Europe.
• International Approvals: Limited compared to domestic; expansion potential hinges on CE marking and country-specific approvals.

Physician and Patient Acceptance

• Physician Adoption: Growing after clinical familiarity; driven by evidence for sustained efficacy.
• Patient Preference: Favor non-invasive or fewer injections; YUTIQ’s 36-month duration aligns well.

Pricing Strategies and Market Penetration

• Premium pricing aligns with sustained-release benefits.
• Competitive pricing could be compromised by entrenched competitors like Ozurdex.

Potential Market Expansion

Region	Market Status	Regulatory Outlook	Opportunities
US	Mature	Clear pathway, insurance coverage	High potential, early mover advantage possible
EU	Growing	CE mark approved	Expansion facilitated by EMA approval
Other Markets	Limited	Varies; regulatory hurdles	Strategic entry via local partnerships

---

Financial Trajectory and Projections

Revenue Forecast Model (US Focus, 2023-2028)

Year	Assumptions	Estimated Revenue	Notes
2023	10% market share of prevalent uveitis patients	~$40 million	Assuming continued physician adoption
2024	15% market share, reimbursement expansion	~$75 million	Expanded reimbursement coverage
2025	20-25% market share, new indications	~$100-125 million	Additional indications targeted
2026-2028	Market saturation, global expansion	$150-200 million	International market penetration

Note: These projections depend on physician acceptance, competition, and regulatory environment.

Cost and Profitability Aspects

Factor	Influence	Implications
Manufacturing Costs	Economies of scale	Reduced per-unit cost with increased volume
R&D Expenses	Limited post-approval	Mostly manufacturing and marketing
Sales & Marketing	Heavily driver of uptake	Investment essential for market penetration
Reimbursement Rates	Affect net revenue	Negotiations and policy advocacy vital

---

Comparative Summary Table

Feature	YUTIQ	Ozurdex	Retisert	Iluvien
Duration	36 months	3-6 months	30 months	36 months
Formulation	Non-biodegradable	Biodegradable	Non-biodegradable	Non-biodegradable
Indications	Posterior uveitis	Multiple, including macular edema	Uveitis, macular edema	Uveitis
Market Penetration	Emerging	Established	Limited	Growing
Advertising & Education	Needed	Well-established	Limited	Active

---

Key Investment Considerations

• Strong Differentiation: Sustained-release formulation with a 36-month duration could gain a competitive edge over existing therapies.
• Market Expansion: Opportunities in Europe and Asia, alongside existing US presence, can significantly improve revenue potential.
• Regulatory Pathways: Ongoing clinical trials and regulatory filings for additional indications are vital to growth.
• Pricing Power: Ability to maintain premium pricing aligned with benefits supports margins.
• Competition Risks: Entrenched competitors with broader indications could diminish market share.

---

Conclusion

YUTIQ presents a promising investment opportunity based on its niche positioning in uveitis management, extended duration of effect, and favorable reimbursement environment in key markets. While competitive landscape and regulatory hurdles exist, the product's potential to capture incremental market share makes it a strategically significant asset for stakeholders focused on ophthalmology and rare disease therapeutics.

---

Key Takeaways

• Market Size & Revenue Potential: US uveitis market estimated to generate up to $50 million in Year 1, with scope for significant growth.
• Competitive Positioning: YUTIQ’s 36-month release distinguishes it from shorter-duration therapies, but market share gains depend on physician adoption and reimbursement policies.
• Global Expansion: Opportunities in Europe and Asia hinge on regulatory approvals, with European markets demonstrating readiness.
• Financial Trajectory: Pathways suggest potential revenues of $100-200 million/year within five years, contingent upon market penetration strategies and competitive dynamics.
• Strategic Focus: Emphasize physician education, differentiated marketing, and clinical data expansion to maximize commercial success.

---

FAQs

Q1: What are the primary factors influencing YUTIQ’s revenue growth?
A1: Physician adoption rate, reimbursement policies, competitive positioning, market expansion, and clinical evidence supporting long-term efficacy.

Q2: How does YUTIQ compare with its main competitor, Ozurdex?
A2: YUTIQ offers a longer duration (36 months) versus Ozurdex’s 3-6 months, which could lead to better patient compliance and economic advantages if marketed effectively.

Q3: What challenges could impact YUTIQ’s market penetration?
A3: Entrenched competitors, limited awareness among physicians, reimbursement delays, and regulatory hurdles in new markets.

Q4: What is the significance of international regulatory approvals for YUTIQ?
A4: Expanding global footprint increases revenue potential, diversifies risk, and enhances competitive positioning.

Q5: How might recent advances in gene therapy and biologics affect YUTIQ’s market?
A5: These therapies could offer longer-term solutions or curative options, potentially limiting YoY growth unless YUTIQ expands indications or demonstrates superior benefits.

---

References

[1] MarketResearch.com, "Global Uveitis Market Analysis," 2022.
[2] American Academy of Ophthalmology, "Uveitis Prevalence & Epidemiology," 2021.